ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Interleukin-2 receptor"

  • 2019 American Transplant Congress

    Peri-Operative Basiliximab is Not Associated with Post-Transplant Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients

    D. Salerno1, N. Lange1, E. Simoneau2, C. Sammons3, D. Bley1, R. S. Brown Jr4, J. Emond2, K. Halazun5

    1Pharmacy, NewYork-Presbyterian Hospital, New York, NY, 2Surgery, Columbia University Irving Medical Center, New York, NY, 3Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, 4Medicine, Weill Cornell Medicine, New York, NY, 5Surgery, Weill Cornell Medicine, New York, NY

    *Purpose: The optimal immunosuppression for liver transplant recipients (LTR) with hepatocellular carcinoma (HCC) is unknown. Basiliximab, an interleukin-2 receptor antagonist (IL-2RA), confers immunosuppression for LTR…
  • 2019 American Transplant Congress

    PD-1+CD3+CD4-CD8- (Double Negative T-cells) Are Early Responders during Kidney Ischemia Reperfusion Injury and Regulated by Non-Classical MHC Molecules

    M. Sadasivam, S. Noel, S. Lee, J. Gong, A. Hamad, H. Rabb

    Johns Hopkins University and School of Medicine, Baltimore, MD

    *Purpose: Unconventional T-cells (e.g. Tregs and γδT-cells) are increasingly recognized for their roles in maintaining homeostasis and protecting non-lymphoid tissues against injury/stress. Double negative (DN)…
  • 2018 American Transplant Congress

    Engineering Regulatory T Cells with Interleukin (IL-)2 Nanogel for Improved Alloimmune Suppression

    S. Eskandari,1 M. Bandeira Melo,2 J. Assaker,1 A. Mansouri,1 S. Cai,1 B. Al Dulaijan,1 M. Mohamed,1 D. Irvine,2 J. Azzi.1

    1Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; 2Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.

    Clinical trials of adoptively transferred regulatory T cells (TRegs) have been hindered by the short lifespan of these transferred TRegs. Systemic injection of low-dose interleukin…
  • 2018 American Transplant Congress

    TLR2 with TCR Signaling Mobilizes Treg Lymphatic Migration

    W. Piao, Y. Xiong, L. Li, V. Saxena, J. Bromberg.

    UMB, MD.

    Background: Regulatory T cells (Treg) express high levels of lymphotoxin (LT) and bind the LT receptor (LTβR) on lymphatic endothelial cells (LEC). This receptor-ligand interaction…
  • 2017 American Transplant Congress

    Utility of IL-2 Complexes in Promoting Vascularized Composite Allograft Survival.

    H. Xu,1 S. Dahiya,2 L. Wang,2 T. Akimova,2 W. Hancock,2,4 S. Levin.3

    1Plastic and Reconstructive Surgery, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia; 3Orthopaedic Surgery, Hospital of the University of Pennsylvania, Philadelphia; 4Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia

    Vascularized composite allografts (VCA) are a novel, life-enhancing form of transplantation (Tx). The complexity of host immune responses to VCA tissues, especially those involving skin,…
  • 2017 American Transplant Congress

    Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients.

    M. Marron-Wojewodzki,1 I. Szwarc,1 C. Rene,2 J.-F. Eliaou,2 G. Mourad,1 M. Le Quintrec.1,3

    1Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier University Hospital, Montpellier, France; 2Departement of Immunology, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France; 3Inserm U1183, IRMB, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France

    Background. In kidney transplantation, de novo donor specific antibodies (dnDSA) are associated with antibody-mediated rejection (AMR) and graft failure. After dnDSA development, 24% of the…
  • 2017 American Transplant Congress

    The Effect of Low-Dose IL-2 in Clinical Facial Transplantation: Molecular and Immunological Response.

    N. Murakami,1 T. Win,1 T. Borges,1 C. Lian,1 G. Murphy,1 E. Bueno,1 R. Clark,1 T. Strom,2 B. Pomahac,1 L. Riella.1

    1Brigham and Women's Hospital, Boston; 2Beth Israel Deaconess Medical Center, Boston

    BackgroundRegulatory T cells (Tregs) play a critical role in immune tolerance and low-dose recombinant IL-2 administration has been reported to expand Tregs in vivo. Although…
  • 2016 American Transplant Congress

    In Vitro Reactivity of CD4+ T Cells Subsets from Hosts with Antigen Specific Transplant Tolerance Mediated by CD4+CD25+T Cells.

    B. Hall, C. Robinson, K. Plain, N. Verma, G. Tran, N. Carter, M. Nomura, R. Boyd, S. Hodgkinson.

    Immune Tolerance Laboratory, UNSW Australia, Sydney, NSW, Australia.

    In animals with transplant tolerance without lympho-hemopoietic chimerism peripheral T cells reactive to donor are not deleted, but their capacity to effect rejection is inhibited…
  • 2016 American Transplant Congress

    Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.

    S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, F. Al Ammary, D. Segev.

    Johns Hopkins, Baltimore, MD.

    Antithymocyte globulin (ATG) is recommended over IL-2 receptor antagonist (IL2) in high-risk recipients for induction immunosuppression. However, “high-risk” status has not been defined in an…
  • 2016 American Transplant Congress

    IL-2 Therapy Restores the Impaired Function of Regulatory T Cells Induced by Calcineurin Inhibitors in Liver Transplantation.

    G. Whitehouse, E. Gray, S. Mastoridis, E. Kodela, A. Sanchez-Fueyo, M. Martinez-Llordella.

    Liver Science Department, King's College London, London, United Kingdom.

    CD4+CD25+FOXP3+ regulatory T cells (Tregs) have an essential role in immune regulation and constitute a key target for cellular immunotherapies in transplantation. IL-2 is critical…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences